Treatment with direct-acting antiviral agents is associated with increased platelet count in patients with chronic hepatitis C

摘要

Platelet count correlates with the liver fibrosis stage of patients with chronic hepatitis C (CHC). Patients with CHC exhibit improvement in platelet count after achieving a sustained virplogical response (SVR) to peg-interferon and ribavirin (RBV) therapy. The temporal effect of direct?acting antiviral agents (DAAs) on platelet count in patients with CHC throughout treatment and after 12 weeks of posttreatment follow-up is unclear. From September 2012 to November 2016, 78 consecutive CHC patients who received a complete course of antiviral therapy with DAAs and without RBV were enrolled in this retrospective study. Demographic features, complete blood counts, biochemical data, and hepatitis C virus ribonucleic acid levels were collected at baseline, week 2, week 4, end of therapy (EOT), and 12 weeks after therapy ,(PW12). The mean age was 52.63 ± 10.11 years, and 40 (51.3%) patients were male. Ttie baseline mean, alanine aminotransferase (ALT) was 75.5 ± 50.0 U/L. The SVR rate.at -12 weeks after therapy (SVR12) was 98.79& (77/78). Mean platelet count increased from 1.73-.0 ± 58.3 X 109/L at baseline to* 186.0 ± 59.0 X 109/L at week 2 (P